Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis Joins Ensemble To Develop An Oral IL-17 Blocker

This article was originally published in The Pink Sheet Daily

Executive Summary

Novartis is the latest big pharma to partner with Ensemble to develop oral small molecules against traditional biologic targets. Novartis will develop Ensemble’s synthetic macrocycle drug targeting IL-17, a pathway the big pharma knows well.

You may also be interested in...

Biocon’s Alzumab Is Priced At Half Of Its Rival Brands, But Will It Change The Game?

The Indian drug manufacturer has taken a giant leap with the launch of its indigenously researched psoriasis treatment. But experts suggest the task to establish it against larger products will be extremely daunting.

Psoriasis Market Snapshot: An Area Drug Makers Are Itching To Get Into

The market for psoriasis drugs will become increasingly competitive, with several drugs with novel mechanisms of action approaching commercialization. Their challenge will be to demonstrate efficacy that stands up to existing biologics and an ultra-clean safety profile, given the notoriously cautious prescriber base.

Ensemble Therapeutics Corp.

Ensemble Therapeutics Corp. believes that its large-scale libraries of chemicals with macrocyclic structures will yield worthy drug candidates and ultimately marketable therapeutics. The hefty size of macrocyclic compounds is the key characteristic that Ensemble is banking on. Whereas small molecules generally interact with their targets by binding to them, Ensemble thinks macrocycles will be big enough to spread across the surface of disease-relevant proteins and so physically disrupt interactions that smaller molecules are too weak to influence. If so, macrocycles could hit targets that only protein therapeutics can address now, and potentially do so orally.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts